The review found no eligible studies for this question.
The review found no eligible studies for this question.
Summary of findings: intravitreal anti‐VEGF plus intravitreal steroid showed no clear difference in systemic adverse events at compared with intravitreal anti‐VEGF (low certainty).
It is very uncertain whether anti‐VEGF changes systemic serious adverse events compared with control (very low certainty).
The intervention showed no clear difference in all serious systemic adverse events (low certainty).
Summary of findings: anti‐VEGF treatment showed no clear difference in serious systemic adverse events at 1 year compared with control (moderate certainty).
Summary of findings: bevacizumab showed no clear difference in serious systemic adverse events at 1 yearb compared with ranibizumab (moderate certainty).
The intervention showed no clear difference in adverse events ‐ serious systemic events at 1 year (moderate certainty).